Inform Genomics has completed the first phase of product development to predict a patient's risk of developing oral mucositis after receiving high-dose chemotherapy prior to hematopoietic stem cell transplant.
The results of this single-center, 153-patient study demonstrated the product's ability to discriminate which patients develop oral mucositis with 99.3% accuracy.
Further development will include validation of these initial results in a multicenter study. Inform Genomics also announced that it entered into a collaboration agreement with Swedish Orphan Biovitrum to further develop and commercialize the product.
The principal investigator for the study, Stephen Sonis, DMD, chief of the Division of Oral Medicine at the Dana-Farber Cancer Institute and professor of oral medicine at the Harvard School of Dental Medicine, will present the study results at the upcoming American Society of Clinical Oncology annual meeting in Chicago.
